ClinicalTrials.gg
CompletedNCT03777059Updated Jul 9, 2021Results posted

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

A Phase 3 interventional study of Atogepant and Placebo in Episodic Migraine, sponsored by Allergan. Completed at 138 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-09.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
910
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
3rd of 21
910 · median 468
Started
2018
with 1 other
Phase 3
15 of 21
3 open now
Registered
3rd of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 3rd largest by enrollment, is one of 2 that started in 2018, is one of 15 in phase 3, and was the 3rd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.

03

Conditions studied

  • Episodic Migraine

Keywords

  • Migraine
  • Aura
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis.
  • Age of the participant at the time of migraine onset \<50 years.

Exclusion criteria

Exclusion Criteria:

  • Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine.
  • Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy.
  • History of an inadequate response to >4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine.
  • Participants with hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
910 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo-matching atogepant tablets orally once daily for 12 weeks.

    Drug: Placebo

  • Experimental
    Atogepant 10 mg

    Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.

    Drug: Atogepant · Drug: Placebo

  • Experimental
    Atogepant 30 mg

    Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.

    Drug: Atogepant · Drug: Placebo

  • Experimental
    Atogepant 60 mg

    Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.

    Drug: Atogepant · Drug: Placebo

Interventions

  • Atogepant tablet

  • DrugPlacebo

    Placebo-matching atogepant tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline (Day -28 to Day -1) to Week 12

Secondary outcomes

  1. Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period

    Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.

    Time frame: Baseline (Day-28 to Day -1) to Week 12

  2. Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period

    Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

    Time frame: Baseline (Day-28 to Day -1) to Week 12

  3. Percentage of Participants With at Least a 50% Reduction (Improvement) in 3-month Average of Monthly Migraine Days

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.

    Time frame: Baseline (Day -28 to Day -1) to Week 12

  4. Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12

    MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.

    Time frame: Baseline (Day 1) to Week 12

  5. Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine-Diary (AIM-D) Across the 12-Week Treatment Period

    The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) performance of daily activities domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.

    Time frame: Baseline (Day -28 to Day -1) to Week 12

  6. Change From Baseline in Mean Monthly Physical Impairment Domain Score of the Activity Impairment in Migraine- Diary (AIM-D) Across the 12-Week Treatment Period

    The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) physical impairment domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.

    Time frame: Baseline (Day -28 to Day -1) to Week 12

07

Results

Posted Jul 9, 2021

Participant flow

DB Treatment Period (Up to Week 12)
Participant flow — DB Treatment Period (Up to Week 12)
MilestonePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Started223222230235
Treated: safety population222221228231
Completed201193207204
Not completed22292331
Withdrew: Adverse event6946
Withdrew: Lack of efficacy1001
Withdrew: Withdrawal by subject89810
Withdrew: Lost to follow-up3345
Withdrew: Pregnancy0100
Withdrew: Protocol deviation4578
Withdrew: Reason not specified0201
Follow-Up Period (Weeks 12 to 16)
Participant flow — Follow-Up Period (Weeks 12 to 16)
MilestonePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Started46543845
Completed41493236
Not completed5569
Withdrew: Withdrawal by subject5345
Withdrew: Lost to follow-up0103
Withdrew: Protocol deviation0110
Withdrew: Reason not specified0011

Outcome measures

PrimaryChange From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days was defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. A Mixed-effects model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline (Day -28 to Day -1) to Week 12
Reported as:
Least squares mean · migraine days per month
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period
migraine days per monthPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period-2.48 ± 0.210-3.69 ± 0.210-3.86 ± 0.206-4.20 ± 0.206
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.21 · 95% CI -1.78 to -0.64
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.38 · 95% CI -1.94 to -0.82
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.72 · 95% CI -2.28 to -1.15
SecondaryChange From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period

Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache qualified by duration or acute symptomatic medication use. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of migraine days during the last 28 days of the Baseline phase, from Day -28 to -1. Negative change from Baseline indicates improvement. MMRM was used for analysis.

Time frame:
Baseline (Day-28 to Day -1) to Week 12
Reported as:
Least squares mean · headache days per month
Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period
headache days per monthPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period-2.52 ± 0.225-3.94 ± 0.225-4.04 ± 0.221-4.23 ± 0.221
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.42 · 95% CI -2.03 to -0.81
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.53 · 95% CI -2.13 to -0.92
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.71 · 95% CI -2.32 to -1.10
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period

Participants recorded allowed medication(s) to treat an acute migraine in the daily diary. The monthly (4-week) acute medication use days was defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline was defined as the number of acute medication use days during the last 28 days of the Baseline phase, from Day -28 to -1. A negative change from Baseline indicates improvement. MMRM was used for the analysis.

Time frame:
Baseline (Day-28 to Day -1) to Week 12
Reported as:
Least squares mean · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period
acute medication use days per monthPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period-2.35 ± 0.184-3.66 ± 0.183-3.68 ± 0.180-3.85 ± 0.180
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.31 · 95% CI -1.81 to -0.82
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.33 · 95% CI -1.82 to -0.83
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.50 · 95% CI -2.00 to -1.01
SecondaryPercentage of Participants With at Least a 50% Reduction (Improvement) in 3-month Average of Monthly Migraine Days

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache qualified by duration or acute symptomatic medication use. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. Each 4-week period was averaged.

Time frame:
Baseline (Day -28 to Day -1) to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 50% Reduction (Improvement) in 3-month Average of Monthly Migraine Days
percentage of participantsPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Percentage of Participants With at Least a 50% Reduction (Improvement) in 3-month Average of Monthly Migraine Days29.055.658.760.8
Statistical analysis
  • Placebo vs Atogepant 10 mg · Regression, Logistic · p = <.0001 (Odds ratio and p-value was based on logistic regression with treatment group, Baseline value, and prior exposure to a migraine prevention medications with proven efficacy as explanatory variables.) · Odds ratio (or): 3.06 · 95% CI 2.05 to 4.56
  • Placebo vs Atogepant 30 mg · Regression, Logistic · p = <.0001 (Odds ratio and p-value was based on logistic regression with treatment group, Baseline value, and prior exposure to a migraine prevention medications with proven efficacy as explanatory variables.) · Odds ratio (or): 3.53 · 95% CI 2.37 to 5.26
  • Placebo vs Atogepant 60 mg · Regression, Logistic · p = <.0001 (Odds ratio and p-value was based on logistic regression with treatment group, Baseline value, and prior exposure to a migraine prevention medications with proven efficacy as explanatory variables.) · Odds ratio (or): 3.82 · 95% CI 2.56 to 5.71
SecondaryChange From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12

MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks. It is divided into three domains: role function-restrictive (questions 1-7, score range 7 to 42) assesses how migraines limit one's daily social and work-related activities; role function-preventive (questions 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the emotional function (questions 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale where 1=none of the time and 6=all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores from Baseline indicate better quality of life. MMRM was used for the analysis.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12
score on a scalePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Migraine-Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 1220.45 ± 1.61730.35 ± 1.63930.53 ± 1.59331.25 ± 1.591
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: 9.90 · 95% CI 5.45 to 14.36
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: 10.08 · 95% CI 5.71 to 14.46
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: 10.80 · 95% CI 6.42 to 15.18
SecondaryChange From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine-Diary (AIM-D) Across the 12-Week Treatment Period

The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) performance of daily activities domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.

Time frame:
Baseline (Day -28 to Day -1) to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine-Diary (AIM-D) Across the 12-Week Treatment Period
score on a scalePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the Activity Impairment in Migraine-Diary (AIM-D) Across the 12-Week Treatment Period-6.09 ± 0.504-7.28 ± 0.500-8.63 ± 0.502-9.41 ± 0.504
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = 0.0856 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.19 · 95% CI -2.56 to 0.17
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = 0.0003 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -2.54 · 95% CI -3.91 to -1.18
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -3.32 · 95% CI -4.68 to -1.96
SecondaryChange From Baseline in Mean Monthly Physical Impairment Domain Score of the Activity Impairment in Migraine- Diary (AIM-D) Across the 12-Week Treatment Period

The AIM-D is a 9-item PRO measure that assesses the impact of migraine on the performance of daily activities and physical impairment using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). Baseline was defined as the monthly (averaged for a month) physical impairment domain score during the last 28 days of the Baseline period from Day -28 to -1. MMRM was used for the analysis.

Time frame:
Baseline (Day -28 to Day -1) to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the Activity Impairment in Migraine- Diary (AIM-D) Across the 12-Week Treatment Period
score on a scalePlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the Activity Impairment in Migraine- Diary (AIM-D) Across the 12-Week Treatment Period-4.03 ± 0.439-5.11 ± 0.436-6.02 ± 0.438-6.49 ± 0.439
Statistical analysis
  • Placebo vs Atogepant 10 mg · Mixed-effects Model for Repeated Measure · p = 0.0743 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.08 · 95% CI -2.27 to 0.11
  • Placebo vs Atogepant 30 mg · Mixed-effects Model for Repeated Measure · p = 0.0011 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -1.99 · 95% CI -3.18 to -0.80
  • Placebo vs Atogepant 60 mg · Mixed-effects Model for Repeated Measure · p = <.0001 (MMRM model included Baseline monthly migraine days as a covariate, treatment group and visit (month) as fixed factors, and treatment group-by-visit and Baseline-by-visit as interaction terms, with an unstructured covariance matrix.) · Least squares mean difference: -2.46 · 95% CI -3.65 to -1.28

Adverse events

Collected over From first dose of study drug through end of study (Up to 16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/223 (0%)2/222 (0.9%)15/222 (6.8%)
Atogepant 10 mg0/222 (0%)2/221 (0.9%)34/221 (15.4%)
Atogepant 30 mg0/230 (0%)0/228 (0%)37/228 (16.2%)
Atogepant 60 mg0/235 (0%)0/231 (0%)32/231 (13.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
Optic neuritisNervous system disorders0/2221/2210/2280/231
AsthmaRespiratory, thoracic and mediastinal disorders0/2221/2210/2280/231
Gastric ulcer haemorrhageGastrointestinal disorders1/2220/2210/2280/231
Brain injuryNervous system disorders1/2220/2210/2280/231
Negative pressure pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/2220/2210/2280/231
Most frequent other events
Most frequent other events
EventPlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mg
ConstipationGastrointestinal disorders1/22217/22116/22816/231
NauseaGastrointestinal disorders4/22211/22110/22814/231
Upper respiratory tract infectionInfections and infestations10/2229/22113/2289/231

Baseline characteristics

Safety Population included all participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(years)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Mean40.3 ± 12.8141.4 ± 12.0542.1 ± 11.6842.5 ± 12.4141.6 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Female198200204199801
Male24212432101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
American Indian or Alaska Native01113
Asian221712
Native Hawaiian or Other Pacific Islander00000
Black or African American24343828124
White194181185192752
More than one race233210
Unknown or Not Reported00011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Hispanic2321191477
Non-Hispanic199200209217825
Monthly Migraine Days
Monthly Migraine Days(migraine days per month)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Mean7.5 ± 2.397.5 ± 2.467.9 ± 2.327.8 ± 2.317.6 ± 2.37
Monthly Headache Days
Monthly Headache Days(headache days per month)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Mean8.4 ± 2.558.4 ± 2.758.8 ± 2.629.0 ± 2.568.7 ± 2.63
Monthly Acute Medication Use
Monthly Acute Medication Use(acute medication use days per month)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Mean6.5 ± 3.156.6 ± 2.996.7 ± 3.026.9 ± 3.176.7 ± 3.08
MSQ v2.1 Role Function-Restrictive Domain Score
MSQ v2.1 Role Function-Restrictive Domain Score(score on a scale)PlaceboAtogepant 10 mgAtogepant 30 mgAtogepant 60 mgTotal
Mean46.8 ± 19.6744.9 ± 21.3744.0 ± 19.6146.8 ± 20.3645.6 ± 20.26

2 further baseline measures are reported on the registry.

08

Study locations

138 sites
  • Synexus Clinical Research US, Inc.
    Chandler, Arizona 85224, United States
  • Advanced Research Associates
    Glendale, Arizona 85308, United States
  • Alea Research Institute
    Phoenix, Arizona 85012, United States
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • Principals Research Group
    Hot Springs, Arkansas 71901, United States
  • Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Med Center Medical Clinic
    Carmichael, California 95608, United States
  • Triwest Research Associates
    El Cajon, California 92020, United States
  • Neuro Pain Medical Center
    Fresno, California 93710, United States
  • California Headache and Balance Center
    Fresno, California 93720, United States
  • Fullerton Neurology and Headache Center
    Fullerton, California 92835, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • NervePro Research Bruce Cleeremans
    Irvine, California 92618, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Torrance Clinical Research Institute, Inc.
    Lomita, California 90731, United States
  • Long Beach Clinical Trials Services
    Long Beach, California 90806, United States
  • Keck Medicine of USC
    Los Angeles, California 90033, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Newport Beach Clinical Research Associates
    Newport Beach, California 92663, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Stanford
    Palo Alto, California 94304, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California 91730, United States
  • Desert Valley Research
    Redlands, California 92374, United States
  • George J. Rederich, M.D. Inc.
    Redondo Beach, California 90277, United States
  • Paradigm Clinical Research Centers, Inc
    San Diego, California 92117, United States
  • Optimus Medical Group
    San Francisco, California 94102, United States
  • California Neuroscience Research
    Sherman Oaks, California 91403, United States
  • Synexus Clinical Research US, Inc.
    Vista, California 92083, United States
  • Colorado Springs Neurological Associates
    Colorado Springs, Colorado 80907, United States
  • Delta Waves, Inc.
    Colorado Springs, Colorado 80918, United States
  • Colorado Neurological Institute
    Englewood, Colorado 80113, United States
  • New England Institute for Clinical Research
    Stamford, Connecticut 06905, United States
  • Aventura Neurological Associates
    Aventura, Florida 33180, United States
  • Neurology Offices of South Florida
    Boca Raton, Florida 33428, United States
  • Sarkis Clinical Trials- Gainesville
    Gainesville, Florida 32607, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Neurology Associates, P.A.
    Maitland, Florida 32751, United States
  • Well Pharma Medical Research, Corp.
    Miami, Florida 33143, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 32801, United States
  • Neurology Associates of Ormond Beach
    Ormond Beach, Florida 32174, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Sarasota Memorial Hospital Clinical Research Center
    Sarasota, Florida 34239, United States
  • Axiom Clinical Research of Florida
    Tampa, Florida 33609, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Neurotrials Research
    Atlanta, Georgia 30328, United States
  • Pediatric and Adolescent NeuroDevelopmental Associates (PANDA) Neurology
    Atlanta, Georgia 30328, United States
  • Synexus Clinical Research US, Inc.
    Atlanta, Georgia 30328, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Diamond Headache Clinic Ltd
    Chicago, Illinois 60642, United States
  • Clinical Investigation Specialists
    Gurnee, Illinois 60031, United States
  • JWM Neurology
    Indianapolis, Indiana 46256, United States
  • Deaconess Clinic - Gateway Health Center
    Newburgh, Indiana 47630, United States
  • PMG Research, Inc. d/b/a PMG Research of McFarland Clinic
    Ames, Iowa 50010, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • College Park Family Care Center
    Overland Park, Kansas 66212, United States
  • Phoenix Medical Research
    Prairie Village, Kansas 66208, United States
  • Heartland Research Associates, LLC - An AMR Company
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC - An AMR Company
    Wichita, Kansas 67207, United States
  • Ochsner Clinic Foundation
    Covington, Louisiana 70433, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • DelRicht Research
    New Orleans, Louisiana 70124, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • Mid-Atlantic Permanente Medical Group, PC
    Largo, Maryland 20774, United States
  • John R. Graham Headache Center Brigham and Women's Faulkner Hospital
    Boston, Massachusetts 02130, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02740, United States
  • Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Synexus Usa
    Bay Saint Louis, Mississippi 63141, United States
  • The Headache Center
    Ridgeland, Mississippi 39157, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC.
    Springfield, Missouri 65810, United States
  • Synexus Clinical Research US, Inc.
    Omaha, Nebraska 68144, United States
  • Nevada Headache Institute
    Las Vegas, Nevada 89113, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Albuquerque Clinical Trials
    Albuquerque, New Mexico 87102, United States
  • Dent Neurologic Institute
    Amherst, New York 14226, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • PMG Research of Charlotte, LLC
    Charlotte, North Carolina 28209, United States
  • Guilford Neurologic Associates, Inc
    Greensboro, North Carolina 27405, United States
  • Raleigh Neurology Associates, P.A.
    Raleigh, North Carolina 27607, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • PMG Research of Rocky Mount, LLC
    Rocky Mount, North Carolina 27804, United States
  • Wilmington Health, PLLC
    Wilmington, North Carolina 28401, United States
  • Piedmont Medical Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Synexus Clinical Research US, Inc.
    Akron, Ohio 44311, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Patient Priority Clinical Sites
    Cincinnati, Ohio 45215, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Sentral Clinical Research Services
    Cincinnati, Ohio 45242, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Family Physicians Associates
    Lyndhurst, Ohio 44124, United States
  • OK Clinical Research, LLC
    Edmond, Oklahoma 73034, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73069, United States
  • Centennial Health-Synexus
    Oklahoma City, Oklahoma 73111, United States
  • Tulsa Clinical Research
    Tulsa, Oklahoma 74104, United States
  • Oregon Center for Clinical Investigations
    Portland, Oregon 97214, United States

Showing the first 100 of 138 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes JT, Creutz L, Gandhi P, Dodick D. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial. Neurology. 2023 Feb 21;100(8):e764-e777. doi: 10.1212/WNL.0000000000201568. Epub 2022 Nov 17. PubMed 36396451 ↗
  • Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 Jun 1;5(6):e2215499. doi: 10.1001/jamanetworkopen.2022.15499. PubMed 35675076 ↗
  • Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14. PubMed 34521260 ↗
  • Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM; ADVANCE Study Group. Atogepant for the Preventive Treatment of Migraine. N Engl J Med. 2021 Aug 19;385(8):695-706. doi: 10.1056/NEJMoa2035908. PubMed 34407343 ↗
  • Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L, Periclou A. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1099-1107. doi: 10.1002/cpdd.940. Epub 2021 May 4. PubMed 33942560 ↗
  • Min KC, Kraft WK, Bondiskey P, Colon-Gonzalez F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci. 2021 Mar;14(2):599-605. doi: 10.1111/cts.12917. Epub 2020 Nov 24. PubMed 33142014 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jun 2020, 18 months.

Results were first posted in Jul 2021, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 18 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2018
First posted
Dec 17, 2018
StartActual
Dec 14, 2018
Primary completionActual
Jun 19, 2020
CompletionActual
Jun 19, 2020
Results first posted
Jul 9, 2021
Last update
Jul 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03777059
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Dec 14, 2018
Primary completion
Jun 19, 2020
Completion
Jun 19, 2020
Results posted
Jul 9, 2021
Last update
Jul 9, 2021

Study contacts

Joel Trugman, MD
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion